

IDS - 09/07/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number		10803344	
		Filing Date		2004-03-17	
		First Named Inventor		Jerome C. Bressi	
		Art Unit		1626	
		Examiner Name		Deborah C. Lambkin	
		Attorney Docket Number		HDAC-5005-U	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
DL	1	WO 2005/034880	WO		2005-04-21	ATON PHARMA, INC.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button


NON-PATENT LITERATURE DOCUMENTS								Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T5

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10803344
	Filing Date	2004-03-17
	First Named Inventor	Jerome C. Bressi
	Art Unit	1626
	Examiner Name	Deborah C. Lambkin
	Attorney Docket Number	HDAC-5005-U

DL	1	Koruznjak et al., "Novel Derivatives of Benzo(b)thieno[2,3-c]quinolones: Synthesis, Photochemical Synthesis, and Antitumor Evaluation," J. Med. Chem., Vol. 46, No. 21, pp. 4516-4524 (2003). <input type="checkbox"/>
DL	2	Wright et al., "The Preparation of 3-Chlorobenzo[b]thiophene Derivatives from Cinnamic Acids, J. Heterocyclic Chem., Vol. 8, No. 5, pp. 711-14 (1971). <input type="checkbox"/>


If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	9/26/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/803,344
Filing Date	March 17, 2004
First Named Inventor	Jerome C. Bressi
Group Art Unit	1626
Examiner Name	Deborah C. Lambkin

Attorney Docket Number

HDAC-5005-U

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
DL	AA	US 5,977,108	11/2/1999	Kouichi Kikuchi et al.	
DL	AB	US 6,099,851	8/8/2000	Kenneth M. Weisman et al.	
DL	AC	US 6,541,661	4/1/2003	Daniel Delorme et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
DL	AD	EP 0 354 549 A2	2/14/1990	Konica Corporation		
DL	AE	EP 0 378 991 A1	7/25/1990	Ciba-Geigy AG		
DL	AF	JP 03 289654	12/19/1991	Konica Corporation		
DL	AG	EP 0 847 992 A1	6/17/1992	Mitsui Chemicals, Inc.		
DL	AH	EP 0570594 A	11/24/1993	SHIONOGI & CO., LTD.		
DL	AI	WO 97/29776 A1	8/21/1997	G.D. Searle & Co.		
DL	AJ	JP 11 095383	4/9/1999	Konica Corporation		
DL	AK	WO 01/70675	9/27/2001	METHYLGENE, INC.		
DL	AL	WO 02/26696	4/4/2002	PROLIFIX LIMITED		
DL	AM	WO 02/46129 A2	6/13/2002	Abbott Laboratories		
DL	AN	WO 03/024448 A2 & A3	3/27/2003	Methyldene, Inc.		
DL	AO	WO 03/039599 A1	5/15/2003	Novartis AG		
DL	AP	WO 03/066579 A2	8/14/2003	Axys Pharmaceuticals		
DL	AQ	WO 2004/046094	6/3/2004	Queen Mary & Westfield College		
DL	AR	WO 2005/019174	3/3/2005	Axys Pharmaceuticals, Inc.		
DL	AS	WO 2005/040161	5/6/2005	S'Bio PTE		
DL	AT	WO 2005/040101	5/6/2005	S'Bio PTE		
DL	AU	WO 2005/073180	8/11/2005	JKUREHA CHEMICAL INDUSTRY COMPANY, LIMITED		
DL	AV	EP 0 847 992 A1	6/17/1992	Mitsui Chemicals, Inc.		

Examiner
Signature

/Deborah Lambkin/

Date
Considered

09/20/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
				Application Number	10/803,344
				Filing Date	March 17, 2004
				First Named Inventor	Jerome C. Bressi
				Group Art Unit	1626
				Examiner Name	Deborah C. Lambkin
Sheet	2	of	2	Attorney Docket Number	HDAC-5005-U

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
DL	AW	Sasho, Setsuya et al. "Preparation and formulation of thiazole derivatives as cell adhesion inhibitors" Jpn. Kokai Tokkyo Koho, 42 pp. CA 127:17674 (1997)			
DL	AX	Wood, Warren J.L. et al. "Substrate activity screening: A fragment-based method for the rapid identification of nonpeptidic protease inhibitors" Journal of the American Chemical Society, (2005), 127(44), 15521-15527 143:452160			
DL	AY	Dai Yujia et al. "Indole amide hydroxamic acids as potent inhibitors of histone deacetylases." BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 11, 2 June 2003 (2003-06-02), pages 1897-1901, XP002331281 ISSN: 0960-894X abstract; figures 1,2; tables 1-4			
DL	AZ	DATABASE BEILSTEIN INSTITUT ZUR FORDERUNG DER WISSENCHAFTEN, FRANKFURT AM MAIN, DE; 2 December 1991 (12/2/1991), XP002331282 Database accession no. 4311238 abstract			
DL	BA	DATABASE BEILSTEIN INSTITUT ZUR FORDERUNG DER WISSENCHAFTEN, FRANKFURT AM MAIN, DE; 2 December 1991 (12/2/1991), XP002331283 Database accession no. 5815061 abstract			
DL	BB	DATABASE BEILSTEIN INSTITUT ZUR FORDERUNG DER WISSENCHAFTEN, FRANKFURT AM MAIN, DE; 2 December 1991 (12/2/1991), XP002331284 Database accession no. 7765459 abstract			
DL	BC	DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2002 XP002325919 Database accession no. AN:2002:217200			
DL	BD	Lam, Patrick Y.S. et al. "Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants" Journal of Medical Chemistry (2003), 46 (21) 4405-4418, CASREACT 140; 12453			

Examiner Signature	/Deborah Lambkin/	Date Considered	09/20/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.